This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Fast track cell, gene & car-t commercialization from concept to robust patient-centric delivery.

Measure Twice, Treat Once: Navigating the regulatory landscape of assay development to ensure high-quality CGT products

Share this article

Research and development of new cellular and gene therapy (CGT) products to treat different therapeutic indications is growing rapidly, and many candidates are progressing in clinical development.

CGTs must be manufactured using processes that ensure a predefined quality of products. Careful monitoring of critical quality attributes and other product characteristics is needed in process development and in manufacturing to ensure product safety and efficacy. Product intermediaries and drug products are assayed using analytical assays that must be validated before regulatory approval.

In this article from BioProcess International, the authors discuss the use of analytical assays in process development and manufacturing, how tests are developed and validated, and current gaps in the analytical tool kit.

Read the full article here...

Share this article

Upcoming event

Cell & Gene Therapy Manufacturing & Commercialization US

18 - 21 Sep 2023, Boston, MA

The Cell, Gene & Immunotherapy Event for Improving Manufacturing Efficiencies, Costs and Quality

Go to site